Importantly, rates of serious infection did not increase with prolonged use of tocilizumab, and serious infections occurred at rates similar to those reported for RA patients treated with TNF inhibitors or other biologic agents [14,15]. This evidence concerns the gene TNF and rheumatoid arthritis.